Elanco Animal Health

Elanco Animal Health Incorporated announced the on-time completion of a 25,000-square-foot manufacturing expansion at its Elwood, Kansas site, boosting its monoclonal antibody production capacity. The $120 million investment, part of a total $150 million commitment through 2028, increases the site's production capacity by more than four times and includes a new pilot plant and quality control laboratory. The expansion supports the phased launch of Befrena, a new anti-IL-31 mAb injection for canine allergic dermatitis, and Trutect, the first approved therapeutic for canine parvovirus. CEO Jeff Simmons noted that customer demand for Befrena is two times above expectations, and the expanded capacity is key to meeting demand as the company anticipates reaching unconstrained levels in early 2027. The project was led by design-build firm Burns & McDonnell.

The longevity and anti-aging wave is expanding into the US pet industry, with many dog and cat owners willing to spend heavily on experimental treatments and products, from anti-aging drugs, peptides, and supplements to red light therapy, even though many approaches still lack clear scientific evidence. US pet spending is expected to hit a record 165 billion dollars this year, while the pet supplement market is valued at 2.9 billion dollars in 2025, and about 10 percent of pet owners buy supplements for senior pets or anti-aging products. Rapamycin, originally used to prevent organ rejection in humans, is being tested in dogs under the TRIAD program at Texas A&M University and the University of Washington, with a target of enrolling 580 dogs. Loyal Animal Health is studying LOY-002 for senior dogs and expects to launch it next year, while Elanco Animal Health invested 368 million dollars in research and development last year in its pet longevity business. Veterinarians warn that using drugs and products without supporting evidence can carry risks, especially when purchased from sources whose quality cannot be verified.

Elanco reported second-quarter results that beat analyst expectations and raised its full-year guidance. Revenue came in at $1.37 billion versus estimates of $1.31 billion, a 10.2% year-over-year increase, while adjusted EPS of $0.34 beat the $0.27 consensus. The company lifted its full-year revenue guidance to $5.12 billion at the midpoint from $5.05 billion and raised adjusted EPS guidance to $1.13, a 6.6% increase. Management attributed the strong performance to momentum in both Pet Health and Farm Animal businesses, with new products Zenrelia and Credelio Quattro driving growth. Analysts on the earnings call focused on pricing dynamics, revenue contributions from new products, sustainability of Zenrelia's first-line usage, and operating expense trends.

The U.S. Food and Drug Administration has issued an Emergency Use Authorization for Elanco Animal Health's CLiK Extra wound spray to prevent New World screwworm infestations in sheep, cattle, goats, swine, camelids, and certain captive and captured wildlife species. The authorization allows application on or around wounds, including those from birth or surgery, but the product is not approved for this use and will not treat active infestations. Elanco also offers Negasunt Powder and Tanidil, which received emergency authorizations earlier this year, as well as the EPA-registered Catron IV spray. The reentry of New World screwworm into the U.S., confirmed by the USDA in June, poses a critical risk to livestock, pets, and wildlife. CLiK Extra will be available through standard product channels, while Negasunt and Tanidil are distributed via APHIS and its National Veterinary Stockpile.

Elanco Animal Health has received U.S. Food and Drug Administration Emergency Use Authorization for its CLiK Extra wound spray, a product designed to prevent New World screwworm infestations in livestock and wildlife. The stock has pulled back 16.12% over the past seven days and 10.88% over 30 days, though its one-year total shareholder return stands at 32.69%. The most followed analyst narrative pegs fair value at $29.79 per share, implying a 25.7% upside from the latest close of $22.12, supported by expectations of six potential blockbuster product launches and innovation revenue growth in 2025. Risks include persistent foreign exchange headwinds and slower-than-expected adoption of new products such as Zenrelia.

Elanco Animal Health reported second-quarter results that exceeded analyst expectations and raised its full-year 2026 outlook. Non-GAAP earnings per share came in at 34 cents, beating estimates by 7 cents, while revenue rose 10.5 percent year-over-year to 1.37 billion dollars, surpassing consensus by 60 million dollars. Adjusted EBITDA reached 288 million dollars with a margin of 21.2 percent. For the full year, the company lifted its innovation revenue target to 1.25 billion dollars and now expects total revenue between 5.09 billion and 5.14 billion dollars, representing 6 to 7 percent organic constant currency growth, up from the prior range of 5.01 billion to 5.085 billion dollars and above the 5.05 billion dollar consensus. Adjusted EBITDA is forecast at 1.01 billion to 1.035 billion dollars, a 13 percent year-over-year increase at the midpoint, while adjusted earnings per share are seen at 1.10 to 1.16 dollars, a 20 percent rise at the midpoint, compared with the earlier guidance of 1.03 to 1.09 dollars and the 1.07 dollar consensus. The company also improved its year-end net leverage ratio target to approximately 3.0 times adjusted EBITDA.

The National Advertising Division determined that PetIQ provided a reasonable basis for its vet-recommended active-ingredient claims for its PetArmor Extend Flea & Tick Collar, but recommended that PetIQ modify or discontinue certain claims regarding market leadership, brand growth, consumer trust, comparative performance, and product attributes. The decision followed a challenge brought by Elanco Animal Health Incorporated, which markets the competing Seresto collar. NAD found that PetIQ’s survey evidence supported the message that veterinarians recommend the imidacloprid and flumethrin active-ingredient combination more than other flea-and-tick collar active-ingredient combinations. However, NAD determined that PetIQ did not provide adequate support for its “#1 Brand in Total Flea & Tick Solutions” claim or its “#1 Fastest Growing Flea & Tick Brand” claim, and recommended those claims be discontinued or modified. NAD also recommended that PetIQ discontinue or modify its “trusted by millions,” duration, comparative performance, and product attribute claims to avoid conveying unsupported messages. PetIQ stated it agrees to comply with the decision.

Indiana's bioscience sector has been rebranded as BioHeartland Indiana, a new unified identity announced at the BIO International Convention in San Diego. The initiative brings together the state's strengths in human health, animal health, and plant science across an ecosystem that generates more than $125 billion in annual economic impact. The region is home to global leaders Eli Lilly, Elanco Animal Health, and Corteva, and its biosciences sector contributes over $100 billion of economic activity to the state. The announcement follows Governor Mike Braun's $1 billion commitment to help life sciences companies accelerate growth over the next ten years. BioHeartland Indiana is led by the CEOs of Central Indiana Corporate Partnership in collaboration with BioCrossroads and AgriNovus Indiana.

Elanco Animal Health plans to establish Elanco Ventures, a corporate venture capital platform backed by a $25 million multi-year commitment to accelerate innovation in animal health. Launching in late 2026, the fund will focus on early-stage companies at Pre-Seed, Seed, and Series A stages, initially targeting therapeutic advancements and supportive technologies. It may also explore opportunities in the broader One Health landscape and will leverage partnerships within the One Health Innovation District in Indianapolis, anchored by Elanco and Purdue University. The platform will be overseen by experienced CVC leader Eric Steager.